Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Non-Current Assets (2023 - 2025)

Historic Non-Current Assets for Genmab A (GMAB) over the last 3 years, with Q4 2025 value amounting to $10.0 billion.

  • Genmab A's Non-Current Assets rose 29729.51% to $10.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.0 billion, marking a year-over-year increase of 29729.51%. This contributed to the annual value of $10.0 billion for FY2025, which is 29729.51% up from last year.
  • According to the latest figures from Q4 2025, Genmab A's Non-Current Assets is $10.0 billion, which was up 29729.51% from $2.6 billion recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Non-Current Assets peaked at $10.0 billion during Q4 2025, and registered a low of $320.0 million during Q4 2023.
  • Moreover, its 3-year median value for Non-Current Assets was $2.5 billion (2024), whereas its average is $2.8 billion.
  • As far as peak fluctuations go, Genmab A's Non-Current Assets surged by 68562.5% in 2024, and later soared by 638.3% in 2025.
  • Genmab A's Non-Current Assets (Quarter) stood at $320.0 million in 2023, then soared by 685.62% to $2.5 billion in 2024, then surged by 297.3% to $10.0 billion in 2025.
  • Its last three reported values are $10.0 billion in Q4 2025, $2.6 billion for Q3 2025, and $2.6 billion during Q2 2025.